The National Institute for Health and Care Excellence (NICE) has recommended first new treatment - 'romosozumab' for osteoporosis for over a decade.
Thousands of people in England and Wales with severe osteoporosis who are at high risk of fracture are set to benefit from a new treatment - romosozumab - after
NICE published the final draft guidance.
Over 20,000 people could be eligible for the treatment according to the company. Clinical trial evidence showed that romosozumab (also known as EVENITY and made by
UCB) followed by alendronic acid is more effective at reducing the risk of fractures than alendronic acid alone.
Osteoporosis is a disease that causes bones to become thin and fragile. Many people with osteoporosis show no symptoms, but they may be at increased risk of fracture.
Osteoporosis leads to nearly 9 million fractures around the world each year, and over 300,000 people per year attend hospitals in the UK with fractures caused by
osteoporosis.
More than 100 NHS clinicians have urged the National Institute for Health and Care Excellence (NICE) to change its decision - declining recommendation of romosozumab, the first new osteoporosis medication for over a decade.
In a joint letter published on January 2, the clinicians warned of the consequences of barring access to the drug to those who suffer the bone-weakening disease.
The joint letter, led by the Royal Osteoporosis Society (ROS), raised concern over the scarcity of the drug pipeline for osteoporosis and lack of public funding for new research.
It quoted recent government research that showed the National Institute for Health Research (NIHR) invested less than £1 million in osteoporosis research in 2020-21, against the £4.6 billion per year cost to the NHS of fractures.
Craig Jones, chief executive of the Royal Osteoporosis Society said: "We're calling on NICE and the applicant company to get back round the table and work with us to ensure equal access to this important new treatment.
Health Benefits of Green Beans for Osteoporosis Green beans is an important part of osteoporosis prevention because it is packed with vitamins and m...
Suffering from Osteoporosis Treatment? Find Best Doctors for Osteoporosis Treatment treatment in Kondapur,Hyderabad at Apollo Hospitals, ranked amongst the best hospitals.
Amgen Inc sued Novartis AG's Sandoz in a federal court in the United States on Monday (May 1), accusing Sandoz's proposed versions of its multibillion-dollar
bone-strengthening drugs Prolia and Xgeva of infringing several patents.
Amgen asked the New Jersey court to block Sandoz's biosimilars of the drugs until its patents expire. One of the patents named in the complaint does not expire
until 2037.
Sandoz declined to comment on the lawsuit on Tuesday. Novartis, which is also named in the complaint, is preparing to spin Sandoz off into a standalone company
later this year.
Amgen's Prolia is used to treat osteoporosis. Xgeva, with the same active ingredient denosumab, treats bone cancer and prevents fractures in bone-cancer patients.
In addition to support the body, bones also serves as a place to store the body's essential minerals. Because of the bone must be maintained, one with attention to food intake. Foods that are high in calcium is needed to increase bone density, but there are some foods and beverages should be avoided because it accelerates bone fragility by removing the minerals.